Join to View Full Profile
210 MARKET STREETSuite 303Kirkland, WA 98033
Phone+1 919-724-0038
Fax+1 919-724-0038
Dr. Lyman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Previously Director of Comparative Effectiveness Research at the Duke Cancer Institute; Senior Fellow Duke Center for Clinical Health Policy Research. Received undergraduate and medical degree from SUNY Buffalo, Internal Medicine residency at UNC Chapel Hill, Clinical Hematology/Oncology Fellowship at Roswell Park and Postdoctoral Fellowship in Biostatistics at the Harvard School of Public Health & Dana Farber Cancer Center. Previously Professor of Medicine and Chief of Medicine at the Moffitt Cancer Center as well as Prof of Epidemiology/Biostatistics and Associate Chair Medicine at USF. Held Thomas Ordway Endowed Chair & Cancer Center Director Albany Medical College & Prof Epidemiology/Biostatistics SUNY Albany and Prof of Medicine, Associate Cancer Center Director and Director of Health Services and Outcomes Research at University of Rochester. Fellow of ASCO, the American College of Physicians, and the Royal College of Physicians. Editor-In-Chief of Cancer Investigation and on Editorial Board of several oncology specialty journals. Serves on Board of Directors of the Hope Foundation for Cancer Research. Dr Lyman states "I have been extremely privileged to work with some of worlds best biostatisticians/trialists over years including postdoctoral for the fellowship with Prof Marvin Zelen at Harvard, Visiting Prof with Prof Stuart Pocock at London School of Hygiene &Tropical Medicine & Prof Doug Altman at Centre for Health Statistics at Oxford now in Public Health Sciences at Fred Hutch enabling my listing among the top 1% of most highly cited investigators by Web of Science for 7 consecutive years with nearly 100,000 citations. Thank you all. https://en.wikipedia.org/wiki/Gary_Herbert_Lyman
https://scholars.duke.edu/person/gary.lyman
Education & Training
Harvard School of Public HealthPost-Doctoral Fellowship, 1981 - 1982
University at BuffaloFellowship, Hematology and Medical Oncology, 1974 - 1977
University of North Carolina HospitalsResidency, Internal Medicine, 1972 - 1974- Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1972
Certifications & Licensure
WA State Medical License 2014 - 2027
NC State Medical License 1972 - 2026
NY State Medical License 1974 - 2009
FL State Medical License 1977 - 2002
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Distinguished Emeritus Member American Society of Hematology, 1976-2023
- America's Top Doctors Castle Connolly, 2005-2015
- America's Top Doctors for Cancer Castle Connolly, 2005-2015
- Join now to see all
Clinical Trials
- A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients Start of enrollment: 2009 Jul 01
Publications & Presentations
PubMed
- Patient-reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials.Bradley D Menz, Natansh D Modi, Ahmad Y Abuhelwa, Nicole M Kuderer, Gary H Lyman
International Journal of Cancer. 2025-11-15 - Inconsistent and Inaccurate Cancer Clinical Trial Reporting of Venous and Arterial Thrombotic Events: An Urgent Call to Action.David C Calverley, Avi Leader, May Anne Cheong, Kristen M Sanfilippo, Ginny Mason
Journal of Clinical Oncology. 2025-09-10 - 2 citationsUnderstanding oncologic emergencies and related emergency department visits and hospitalizations: a systematic review.Sule Yilmaz, Komal Aryal, Jasmine King, Jason J Bischof, Arthur S Hong
BMC Emergency Medicine. 2025-03-05
Journal Articles
- Aligning Cancer Clinical Trials with Cancer BurdenNicole M Kuderer, Gary H Lyman, JAMA Oncology
- Association of Generic Imatinib Availability and Pricing with Trends in Tyrosine Kinase Inhibitor Use in Patients with Chronic Myelogenous LeukemiaGary Lyman, MD, JAMA Oncology
Abstracts/Posters
- Health Care Costs Associated with Contemporary Chronic Myelogenous Leukemia (CML) Therapy Compared to Other Hematologic Malignancies (HEM)Gary H. Lyman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Cancer Associated Thrombosis Is Associated with Higher Mortality across All Khorana Score Risk LevelsGary H. Lyman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Meta-Analysis and Cost-Effectiveness Analysis of Low-Dose Direct Oral Anticoagulant for the Prevention of Cancer Associated ThrombosisGary H. Lyman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Oncology’s Side Effect Disconnect: The Messy RealityAugust 5th, 2025
Gary Herbert LymanApril 21st, 2024- Risk of Chemotherapy-Induced Febrile Neutropenia in Intermediate-Risk Regimens: Clinical and Economic Outcomes of Granulocyte Colony-Stimulating Factor ProphylaxisFebruary 1st, 2023
- Join now to see all
Professional Memberships
- Fellow
- Member
- Member
- Fellow
- Fellow
External Links
- Wikipediahttps://en.wikipedia.org/wiki/Gary_Herbert_Lyman
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
